- Home
- IMUX vs EVTL Comparison
IMUX vs EVTL Comparison
Compare IMUX & EVTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- EVTL
- Stock Information
- Founded
- IMUX 2016
- EVTL 2016
- Country
- IMUX United States
- EVTL United Kingdom
- Employees
- IMUX N/A
- EVTL N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- EVTL Aerospace
- Sector
- IMUX Health Care
- EVTL Industrials
- Exchange
- IMUX Nasdaq
- EVTL Nasdaq
- Market Cap
- IMUX 86.3M
- EVTL 91.5M
- IPO Year
- IMUX N/A
- EVTL N/A
- Fundamental
- Price
- IMUX $0.98
- EVTL $4.98
- Analyst Decision
- IMUX Strong Buy
- EVTL Buy
- Analyst Count
- IMUX 6
- EVTL 4
- Target Price
- IMUX $12.67
- EVTL $9.50
- AVG Volume (30 Days)
- IMUX 1.0M
- EVTL 696.7K
- Earning Date
- IMUX 02-20-2025
- EVTL 03-13-2025
- Dividend Yield
- IMUX N/A
- EVTL N/A
- EPS Growth
- IMUX N/A
- EVTL N/A
- EPS
- IMUX N/A
- EVTL N/A
- Revenue
- IMUX N/A
- EVTL N/A
- Revenue This Year
- IMUX N/A
- EVTL N/A
- Revenue Next Year
- IMUX N/A
- EVTL N/A
- P/E Ratio
- IMUX N/A
- EVTL N/A
- Revenue Growth
- IMUX N/A
- EVTL N/A
- 52 Week Low
- IMUX $0.92
- EVTL $3.55
- 52 Week High
- IMUX $2.11
- EVTL $15.99
- Technical
- Relative Strength Index (RSI)
- IMUX 44.34
- EVTL 37.20
- Support Level
- IMUX $0.94
- EVTL $4.71
- Resistance Level
- IMUX $1.02
- EVTL $5.33
- Average True Range (ATR)
- IMUX 0.06
- EVTL 0.62
- MACD
- IMUX 0.00
- EVTL -0.22
- Stochastic Oscillator
- IMUX 44.96
- EVTL 6.45
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About EVTL Vertical Aerospace Ltd.
Vertical Aerospace Ltd is engaged in making air travel personal, on-demand, and carbon-free. The company is a global aerospace and technology company that is pioneering electric aviation, focused on designing, manufacturing, and selling a zero operating emission eVTOL aircraft for use in the AAM market, using the technology from the aerospace, automotive, and energy industries. The VX4, Vertical's flagship aircraft, is a piloted electric vertical take-off and landing (eVTOL) vehicle capable of carrying four passengers. The Group operates as a single operating segment and one reporting segment, being the development and commercialization of eVTOL technology.